大剂量利玛图毒素B治疗慢性唾液病：2万单位注射的安全性和有效性报告。

IF 2.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Toxicon Pub Date : 2025-02-04 DOI:10.1016/j.toxicon.2025.108276

Ali Zare Dehnavi , Farzin Pedouim , Rodolfo Savica , Khashayar Dashtipour

{"title":"大剂量利玛图毒素B治疗慢性唾液病：2万单位注射的安全性和有效性报告。","authors":"Ali Zare Dehnavi , Farzin Pedouim , Rodolfo Savica , Khashayar Dashtipour","doi":"10.1016/j.toxicon.2025.108276","DOIUrl":null,"url":null,"abstract":"<div><div>Chronic sialorrhea is a debilitating condition commonly seen in patients with neurological disorders such as cerebral palsy. RimabotulinumtoxinB (RIMA) is approved for treating sialorrhea, with a recommended dose range of 1500–3500 units. We report a case of a 48-year-old female with spastic quadriplegic cerebral palsy, profound intellectual disability, and chronic sialorrhea who was treated with progressively higher doses of RIMA, culminating in a dose of 20,000 units administered via injections into the parotid and submandibular glands. So far, the patient has received 22 treatment cycles of high-dosage RIMA spaced three months apart with remarkable improvement in sialorrhea without any severe adverse effects. This case demonstrates the potential safety and efficacy of using RIMA at a dose of 20,000 units for managing refractory chronic sialorrhea in patients with cerebral palsy, warranting further research into higher dosing regimens.</div></div>","PeriodicalId":23289,"journal":{"name":"Toxicon","volume":"256 ","pages":"Article 108276"},"PeriodicalIF":2.6000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"High-dose rimabotulinumtoxinB for chronic sialorrhea: A case report on the safety and efficacy of 20,000 Units injection\",\"authors\":\"Ali Zare Dehnavi , Farzin Pedouim , Rodolfo Savica , Khashayar Dashtipour\",\"doi\":\"10.1016/j.toxicon.2025.108276\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Chronic sialorrhea is a debilitating condition commonly seen in patients with neurological disorders such as cerebral palsy. RimabotulinumtoxinB (RIMA) is approved for treating sialorrhea, with a recommended dose range of 1500–3500 units. We report a case of a 48-year-old female with spastic quadriplegic cerebral palsy, profound intellectual disability, and chronic sialorrhea who was treated with progressively higher doses of RIMA, culminating in a dose of 20,000 units administered via injections into the parotid and submandibular glands. So far, the patient has received 22 treatment cycles of high-dosage RIMA spaced three months apart with remarkable improvement in sialorrhea without any severe adverse effects. This case demonstrates the potential safety and efficacy of using RIMA at a dose of 20,000 units for managing refractory chronic sialorrhea in patients with cerebral palsy, warranting further research into higher dosing regimens.</div></div>\",\"PeriodicalId\":23289,\"journal\":{\"name\":\"Toxicon\",\"volume\":\"256 \",\"pages\":\"Article 108276\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-02-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Toxicon\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0041010125000509\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Toxicon","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041010125000509","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

慢性唾液是一种使人衰弱的疾病，常见于脑瘫等神经系统疾病患者。rimabotulintoxin B （RIMA）被批准用于治疗唾液病，推荐剂量范围为1500-3500单位。我们报告了一例48岁的女性痉挛性四肢瘫痪性脑瘫、重度智力残疾和慢性唾液病，她接受了渐进式高剂量的RIMA治疗，最终剂量为20,000单位，通过注射到腮腺和下颌骨腺。到目前为止，患者已接受了22个高剂量RIMA治疗周期，间隔3个月，唾液明显改善，无严重不良反应。该病例证明了使用2万单位剂量的RIMA治疗脑瘫患者难治性慢性唾液漏的潜在安全性和有效性，值得进一步研究更高剂量的方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

High-dose rimabotulinumtoxinB for chronic sialorrhea: A case report on the safety and efficacy of 20,000 Units injection

Chronic sialorrhea is a debilitating condition commonly seen in patients with neurological disorders such as cerebral palsy. RimabotulinumtoxinB (RIMA) is approved for treating sialorrhea, with a recommended dose range of 1500–3500 units. We report a case of a 48-year-old female with spastic quadriplegic cerebral palsy, profound intellectual disability, and chronic sialorrhea who was treated with progressively higher doses of RIMA, culminating in a dose of 20,000 units administered via injections into the parotid and submandibular glands. So far, the patient has received 22 treatment cycles of high-dosage RIMA spaced three months apart with remarkable improvement in sialorrhea without any severe adverse effects. This case demonstrates the potential safety and efficacy of using RIMA at a dose of 20,000 units for managing refractory chronic sialorrhea in patients with cerebral palsy, warranting further research into higher dosing regimens.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Toxicon 医学-毒理学

CiteScore

4.80

自引率

10.70%

发文量

358

审稿时长

68 days

期刊介绍： Toxicon has an open access mirror Toxicon: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. An introductory offer Toxicon: X - full waiver of the Open Access fee. Toxicon''s "aims and scope" are to publish: -articles containing the results of original research on problems related to toxins derived from animals, plants and microorganisms -papers on novel findings related to the chemical, pharmacological, toxicological, and immunological properties of natural toxins -molecular biological studies of toxins and other genes from poisonous and venomous organisms that advance understanding of the role or function of toxins -clinical observations on poisoning and envenoming where a new therapeutic principle has been proposed or a decidedly superior clinical result has been obtained. -material on the use of toxins as tools in studying biological processes and material on subjects related to venom and antivenom problems. -articles on the translational application of toxins, for example as drugs and insecticides -epidemiological studies on envenoming or poisoning, so long as they highlight a previously unrecognised medical problem or provide insight into the prevention or medical treatment of envenoming or poisoning. Retrospective surveys of hospital records, especially those lacking species identification, will not be considered for publication. Properly designed prospective community-based surveys are strongly encouraged. -articles describing well-known activities of venoms, such as antibacterial, anticancer, and analgesic activities of arachnid venoms, without any attempt to define the mechanism of action or purify the active component, will not be considered for publication in Toxicon. -review articles on problems related to toxinology. To encourage the exchange of ideas, sections of the journal may be devoted to Short Communications, Letters to the Editor and activities of the affiliated societies.